Prognostic Value of Systemic Immune-Inflammation Index-Based Nomogram in Patients with Extrahepatic Cholangiocarcinoma Treated by Percutaneous Transhepatic Biliary Stenting Combined with ¹²⁵I Seed Intracavitary Irradiation

References

• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. doi:10.1038/s41575-020-0310-z
   PubMed Web of Science ®Google Scholar
• Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19(1):2. doi:10.1007/s11894-017-0542-4
   PubMedGoogle Scholar
• Cai Y, Cheng N, Ye H, Li F, Song P, Tang W. The current management of cholangiocarcinoma: a comparison of current guidelines. Biosci Trends. 2016;10(2):92–102. doi:10.5582/bst.2016.01048
   PubMed Web of Science ®Google Scholar
• Lewis HL, Rahnemai-Azar AA, Dillhoff M, Schmidt CR, Pawlik TM. Current Management of Perihilar Cholangiocarcinoma and Future Perspectives. Chirurgia. 2017;112(3):193–207. doi:10.21614/chirurgia.112.3.193
   PubMedGoogle Scholar
• Ricci AD, Rizzo A, Brandi G. Immunotherapy in Biliary Tract Cancer: worthy of a Second Look. Cancer Control. 2020;27(3):1073274820948047. doi:10.1177/1073274820948047
   Web of Science ®Google Scholar
• Viscardi G, Tralongo AC, Massari F, et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022;177:175–185. doi:10.1016/j.ejca.2022.09.031
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs. 2021;30(4):343–350. doi:10.1080/13543784.2021.1897102
   PubMed Web of Science ®Google Scholar
• Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017;116:11–31. doi:10.1016/j.critrevonc.2016.11.012
   PubMed Web of Science ®Google Scholar
• Indar AA, Lobo DN, Gilliam AD, et al. Percutaneous biliary metal wall stenting in malignant obstructive jaundice. Eur J Gastroenterol Hepatol. 2003;15(8):915–919. doi:10.1097/00042737-200308000-00013
   PubMed Web of Science ®Google Scholar
• Li ZM, Jiao DC, Han XW, Lei QY, Zhou XL, Xu M. Preliminary application of brachytherapy with double-strand 125I seed and biliary drainage for malignant obstructive jaundice. Surg Endosc. 2022;36(7):4932–4938. doi:10.1007/s00464-021-08848-6
   PubMed Web of Science ®Google Scholar
• Xiang Y, Lu S, Li Y, Liu Z, Wang W. Iodine-125 seed Combined With Biliary Stent Placement Versus Stent Placement Alone For Unresectable Malignant Biliary Obstruction: a Meta-Analysis Of Randomized Controlled Trials. J Cancer. 2021;12(5):1334–1342. doi:10.7150/jca.49663
   PubMed Web of Science ®Google Scholar
• Zhou W, Kuang T, Han X, et al. Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms. Endocr Connect. 2020;9(4):289–298. doi:10.1530/EC-19-0541
   PubMed Web of Science ®Google Scholar
• Scilla KA, Bentzen SM, Lam VK, et al. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. Oncologist. 2017;22(6):737–742. doi:10.1634/theoncologist.2016-0443
   PubMed Web of Science ®Google Scholar
• Toyoda J, Sahara K, Maithel SK, et al. ASO Visual Abstract: prognostic Utility of Systemic Immune-Inflammation Index After Resection of Extrahepatic Cholangiocarcinoma-Results from the US Extrahepatic Biliary Malignancy Consortium. Ann Surg Oncol. 2022;29(12):7617–7618. doi:10.1245/s10434-022-12269-7
   Web of Science ®Google Scholar
• Olmez OF, Bilici A, Gursoy P, et al. Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib. Pulmonology. 2022:21. doi: 10.1016/j.pulmoe
   Web of Science ®Google Scholar
• Yang C, Hu BW, Tang F, et al. Prognostic Value of Systemic Immune-Inflammation Index (SII) in Patients with Glioblastoma: a Comprehensive Study Based on Meta-Analysis and Retrospective Single-Center Analysis. J Clin Med. 2022;11:24. doi:10.3390/jcm11247514
   Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang XL, Yan ZP, et al. The use of ¹²5I seed strands for intraluminal brachytherapy of malignant obstructive jaundice[J]. Cancer Biother Radiopharm. 2012;27(5):317–323. doi:10.1089/cbr.2011.0999
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Hu D, Lin Y, Liu F, et al. Elevated Preoperative Platelet to Lymphocyte Ratio Indicates Poor Survival in Patients with Resected High-grade Serous Ovarian Carcinoma. Clin Lab. 2016;62(8):1443–1449. doi:10.7754/Clin.Lab.2016.151137
   PubMed Web of Science ®Google Scholar
• YaKitano Y, Yamashita YI, Yamamura K, et al. Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma. Anticancer Res. 2017;37(6):3229–3237. doi:10.21873/anticanres.11685
   PubMed Web of Science ®Google Scholar
• Terasaki F, Sugiura T, Okamura Y, et al. Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma. Surg Today. 2021;51(10):1602–1609. doi:10.1007/s00595-021-02312-7
   PubMed Web of Science ®Google Scholar
• Kumamoto Y, Kaizu T, Tajima H, et al. Neutrophil-to-lymphocyte ratio as a predictor of postoperative morbidity in patients with distal cholangiocarcinoma. Mol Clin Oncol. 2018;9(4):362–368. doi:10.3892/mco.2018.1698
   PubMed Web of Science ®Google Scholar
• Moses K, Brandau S. Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol. 2016;28(2):187–196. doi:10.1016/j.smim.2016.03.018
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang W, Yuan X, Fu M, Qian H, Xu W. [Corrigendum] Neutrophils in cancer development and progression: roles, mechanisms, and implications (Review). Int J Oncol. 2017;50(2):745. doi:10.3892/ijo.2016.3764
   PubMed Web of Science ®Google Scholar
• Schumacher D, Strilic B, Sivaraj KK, et al. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24(1):130–137. doi:10.1016/j.ccr.2013.05.008
   PubMed Web of Science ®Google Scholar
• Stanger BZ, Kahn ML. Platelets and tumor cells: a new form of border control. Cancer Cell. 2013;24(1):9–11. doi:10.1016/j.ccr.2013.06.009
   PubMed Web of Science ®Google Scholar
• Chumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1016/j.ccr.2013.05.008
   PubMed Web of Science ®Google Scholar
• Tan DW, Fu Y, Su Q, et al. Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: a Meta-analysis. Sci Rep. 2016;6:33789. doi:10.1038/srep33789
   PubMed Web of Science ®Google Scholar
• D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231. doi:10.1016/j.jhep.2005.10.013
   PubMed Web of Science ®Google Scholar
• Coelen RJ, Wiggers JK, Nio CY, et al. Preoperative computed tomography assessment of skeletal muscle mass is valuable in predicting outcomes following hepatectomy for perihilar cholangiocarcinoma. HPB (Oxford). 2015;17(6):520–528. doi:10.1111/hpb.12394
   PubMed Web of Science ®Google Scholar
• Zhang D, Zeng H, Pan Y, et al. Liver Tumor Markers, HALP Score, and NLR: simple, Cost-Effective, Easily Accessible Indexes for Predicting Prognosis in ICC Patients after Surgery. J Pers Med. 2022;12:12. doi:10.3390/jpm12122041
   Web of Science ®Google Scholar
• Sinha SR, Prakash P, Singh RK, Sinha DK. Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer. World J Gastrointest Surg. 2022;14(11):1272–1284. doi:10.4240/wjgs.v14.i11.1272
   PubMed Web of Science ®Google Scholar
• Tella SH, Kommalapati A, Yadav S, et al. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol. 2020;46(5):789–795. doi:10.1016/j.ejso.2020.01.016
   PubMed Web of Science ®Google Scholar
• Yang H, Wang J, Li Z, et al. Risk Factors and Outcomes of Early Relapse After Curative Resection of Intrahepatic Cholangiocarcinoma. Front Oncol. 2019;9:854. doi:10.3389/fonc.2019.00854
   PubMed Web of Science ®Google Scholar
• Kato A, Shimizu H, Ohtsuka M, et al. Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery. Ann Surg Oncol. 2015;22:S1093–1099. doi:10.1245/s10434-015-4768-9
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Casadei-Gardini A, Brieau B, et al. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. Int J Cancer. 2020;147(11):3177–3188. doi:10.1002/ijc.33146
   PubMed Web of Science ®Google Scholar
• Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25(12):2328–2338. doi:10.1093/annonc/mdu162
   PubMed Web of Science ®Google Scholar
• Cron GO, Beghein N, Crokart N, et al. Changes in the tumor microenvironment during low-dose-rate permanent seed implantation iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2005;63(4):1245–1251. doi:10.1016/j.ijrobp.2005.07.971
   PubMed Web of Science ®Google Scholar